Diplomat pharmacy, inc. (DPLO)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Net sales

1,301,197

1,287,624

-

-

1,373,334

1,416,078

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net sales

-

-

1,256,808

-

-

-

1,342,484

1,155,069

1,124,957

1,126,464

1,078,740

1,144,839

1,181,173

1,088,506

995,870

986,824

946,913

808,011

624,883

612,075

595,529

541,675

465,677

398,627

Cost of sales

1,237,812

1,214,897

1,177,588

1,266,771

1,279,976

1,317,662

1,252,106

1,097,777

1,059,867

1,059,750

993,691

1,120,273

1,102,661

1,005,236

916,632

910,159

871,150

738,342

583,741

571,178

555,364

512,107

436,168

375,497

Gross profit

63,385

72,727

79,220

93,857

93,358

98,416

90,378

57,292

65,090

66,714

85,049

24,566

78,512

83,270

79,238

76,665

75,763

69,669

41,142

40,897

40,165

29,568

29,509

23,130

Selling, general and administrative expenses

74,993

80,816

82,868

79,902

83,419

90,642

81,687

54,426

62,782

61,871

76,501

12,957

77,138

69,416

54,194

69,664

48,860

62,474

36,304

42,226

34,306

27,485

23,539

19,331

Goodwill impairments

122,076

122,891

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairments of definite-lived intangible assets

34,173

17,979

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income from operations

-167,857

-148,959

-3,648

-293,689

9,939

7,774

8,691

2,866

2,308

4,843

8,548

6,805

1,374

13,854

25,044

7,001

26,903

7,195

4,838

-1,329

5,859

2,083

5,970

3,799

Other (expense) income:
Interest expense

11,659

10,170

10,215

10,652

10,179

10,392

10,427

4,682

2,054

1,931

2,049

1,787

1,831

1,521

1,434

1,473

1,542

1,903

321

899

734

365

530

512

Impairment of non-consolidated entities

-

-

-

-

286

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity loss and impairment of non-consolidated entities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,121

-377

-309

-401

-319

Change in fair value of redeemable common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,916

957

-

-

Termination of existing stock redemption agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,842

-

-

-

Other

149

101

181

570

574

394

418

101

45

34

33

109

49

105

107

38

90

75

105

465

146

49

468

40

Total other expense

-11,510

-10,069

-10,034

-10,125

-9,891

-9,998

-10,009

-4,581

-2,009

-1,897

-2,016

-6,337

-1,782

-1,416

-1,327

-1,435

-1,452

-1,828

-216

-4,355

1,109

332

-463

-

(Loss) income before income taxes

-179,367

-159,028

-13,682

-303,814

48

-2,224

-1,318

-1,715

299

2,946

6,532

468

-408

12,438

23,717

5,566

25,451

5,367

4,622

-5,684

6,968

2,415

5,507

3,008

Income tax benefit (expense)

-2,087

434

619

-5,790

-121

1,740

-868

-8,227

-662

-544

2,307

1,752

-3,236

4,145

8,534

2,262

9,768

2,254

1,950

-2,329

2,427

740

3,817

-

Net (loss) income

-177,280

-159,462

-14,301

-298,024

169

-3,964

-450

6,512

961

3,490

4,225

-1,284

2,828

8,293

15,183

3,304

15,683

3,113

2,672

-3,355

4,541

1,675

1,690

3,008

Less net loss attributable to noncontrolling interest

-

-

-

-

-

-

-

-24

-55

-101

-142

-186

-2,580

-241

-246

-263

-278

-277

-186

-

-

-

-

-

Net (loss) income attributable to Diplomat Pharmacy, Inc.

-

-

-

-

-

-

-

6,536

1,016

3,591

4,367

-1,098

5,408

8,534

15,429

3,567

15,961

3,390

2,858

-3,130

4,541

1,675

1,690

3,008

Other comprehensive (loss) income, net of tax

-307

-3,358

-2,127

-

918

-962

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive (loss) income

-177,587

-162,820

-16,428

-302,272

1,087

-4,926

-450

-

1,016

3,591

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income per common share, basic and diluted

-2.35

-2.13

-0.19

-

0.00

-0.05

-0.01

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding, basic and diluted (in shares)

-

74,730

74,460,990

-

-

74,158

73,996,313

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income allocable to preferred shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-688

745

299

102

-

Net income allocable to common shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,442

3,796

1,376

1,588

3,008

Basic (in dollars per share)

-

-

-

-

-

-

-

0.10

0.01

0.05

0.07

-0.02

0.08

0.13

0.24

0.06

0.25

0.05

0.06

-0.09

0.12

0.04

0.05

0.09

Diluted (in dollars per share)

-

-

-

-

-

-

-

0.11

0.01

0.05

0.06

-0.02

0.08

0.13

0.23

0.07

0.24

0.05

0.05

-0.09

0.11

0.04

0.05

0.09

Basic (in shares)

75,509

-

-

-

74,386

-

-

69,734

68,371

67,528

66,886

66,746

66,511

66,085

64,539

64,606

63,890

62,610

51,813

49,613

31,643

30,748

32,044

33,142

Diluted (in shares)

75,509

-

-

-

74,741

-

-

70,358

68,769

68,211

67,780

67,951

68,359

68,034

67,844

67,318

65,513

64,795

54,760

52,306

33,670

33,304

34,935

33,936